Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in extensive stage small cell lung cancer
NCT02934503Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Jan 2017
- Primary completion
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in small cell lung cancer (SCLC) (4 cohorts), sponsored by NYU Langone Health. Primary endpoint: Change in PD-L1 Expression Status as Determined by Immunohistochemistry at 5 months. Started Jan 2017; status: terminated.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02934503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02934503.